

Supplementary Table 3. Comparison of clinical outcome measures according to the presence of sarcopenia in patients with AAV

Clinical outcome	Sarcopenia group (n = 30)	Non-sarcopenia group (n = 87)	p value
Mortality (+)	5 (16.7)	10 (11.5)	0.467
Mortality (–)	25 (83.3)	77 (88.5)	
ESRD (+)	6 (20.0)	14 (16.1)	0.625
ESRD (–)	24 (80.0)	73 (83.9)	
Disease relapse (+)	9 (30.0)	25 (28.7)	0.896
Disease relapse (–)	21 (70.0)	62 (71.3)	
Acute coronary syndrome (+)	0	4 (4.6)	0.571
Acute coronary syndrome (–)	30 (100.0)	83 (95.4)	
Stroke (+)	1 (3.3)	6 (6.9)	0.676
Stroke (–)	29 (96.7)	81 (93.1)	

Values are expressed as number (%).

AAV, anti-neutrophil cytoplasmic antibody-associated vasculitis; ESRD, end-stage renal disease.